14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $199.92 $199.92 Thursday, 14th Sep 2023 RXDX stock ended at $199.92. During the day the stock fluctuated 0% from a day low at $199.92 to a day high of $199.92.
90 days $199.92 $199.92
52 weeks $30.75 $199.96

Historical Prometheus Biosciences Inc prices

Date Open High Low Close Volume
May 26, 2023 $198.62 $198.72 $198.51 $198.60 1 070 413
May 25, 2023 $198.70 $198.74 $198.57 $198.60 2 172 849
May 24, 2023 $198.67 $198.80 $198.60 $198.67 1 687 227
May 23, 2023 $198.80 $198.99 $198.68 $198.70 2 677 511
May 22, 2023 $192.50 $193.58 $192.42 $193.45 864 416
May 19, 2023 $193.25 $193.30 $192.16 $192.50 890 357
May 18, 2023 $192.91 $193.25 $192.69 $193.15 694 177
May 17, 2023 $193.00 $193.24 $192.50 $192.94 1 108 128
May 16, 2023 $190.63 $193.50 $189.76 $192.53 1 688 580
May 15, 2023 $194.00 $194.45 $193.90 $194.43 766 788
May 12, 2023 $193.85 $193.99 $193.21 $193.90 722 833
May 11, 2023 $194.15 $194.25 $193.72 $193.80 798 819
May 10, 2023 $194.50 $194.50 $194.01 $194.16 920 164
May 09, 2023 $194.23 $194.67 $194.23 $194.40 941 162
May 08, 2023 $194.25 $194.45 $194.16 $194.22 617 289
May 05, 2023 $194.25 $194.60 $193.99 $194.20 854 251
May 04, 2023 $194.11 $194.22 $193.62 $193.99 1 151 449
May 03, 2023 $194.30 $194.50 $193.95 $194.28 1 302 242
May 02, 2023 $194.49 $194.49 $194.00 $194.04 842 165
May 01, 2023 $194.00 $197.83 $193.81 $194.20 1 192 125
Apr 28, 2023 $194.04 $194.50 $193.91 $193.95 960 564
Apr 27, 2023 $194.25 $195.00 $193.92 $194.00 1 746 575
Apr 26, 2023 $194.11 $194.46 $193.91 $194.33 591 371
Apr 25, 2023 $194.25 $194.53 $194.01 $194.15 778 847
Apr 24, 2023 $194.21 $194.73 $194.01 $194.40 1 011 229
Click to get the best stock tips daily for free!

About Prometheus Biosciences Inc

Prometheus Biosciences Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated ... RXDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT